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| INTRODUCTION
Advancement of novel pharmaceutical agents to the market is often thwarted by lack of selectivity and solubility in physiological solvents.
Various nanoscale delivery vehicles have been considered to address these issues, such as liposomes, micelles, and protein capsules. Of particular interest is protein capsule apoferritin (AFt), which has been successfully used for development of biohybrid and self-assembled materials, 1, 2 for the encapsulation of proteins 3 and small drug molecules. [4] [5] [6] [7] [8] AFt consists of 24 polypeptide subunits assembled into a spherical protein cage with an internal cavity of 8 nm in diameter 9 ;
0.3-to 0.4-nm channels in the shell 10 and pH-dependent dissembly 9 allow controlled release of cargo. The uniform size, biocompatibility, biodegradability, and non-toxicity has led to AFt being identified as an ideal drug delivery vehicle. 11 AFt is internalized into cells by transferrin receptor (TfR)-mediated endocytosis; TfRs are upregulated and highly expressed on cell membranes in many cancers (including colon and breast cancinomas). 12 AFt as a drug delivery vehicle can lead to enhanced delivery to cancer tissue, via exploitation of the enhanced permeability and retention (EPR) associated with the tumour microenvironment, 13 leading to increased intracellular drug concentrations within a tumour, improving the therapeutic efficacy and decreasing side effects. 14 The benzothiazole structure is important in medicinal chemistry, as derivatives of this scaffold possess anticancer, 15 antibacterial, 16 antiviral, 17 antimalarial, 18 and antifungal 19 activity. From this scaffold, a chemistrydriven drug discovery project resulted in the development of a wide range of 2-phenylbenzothiazoles with oxygenated substituents in the phenyl moiety. In a library of more than 35 close structural analogues, one compound 5-fluoro-2-(3,4-dimethoxyphenyl) benzothiazole (GW 610), showed outstanding potent and selective anticancer activity against, eg, colorectal and breast carcinoma models. 15 GW 610 is a potent aryl hydrocarbon receptor (AhR) ligand, bioactivated via cytochrome P450 (CYP) 1A1 and 2W1 catalysis to electrophilic species that generate lethal DNA adducts in sensitive cancer cells. [20] [21] [22] However, GW 610 is highly lipophilic and poorly water soluble;
hence, drug delivery tools are needed to help solubilize and target GW 610. During biotransformation, GW 610 initially undergoes regiospecific demethylation to give 5-fluoro-2-(4-hydroxy-3-methoxyphenyl) benzothiazole (GW 608). 21 The exposed 4′-hydroxy group in GW 608 allows conjugation of substituents via an ester linkage to the benzothiazoles and could lead to enhanced aqueous solubility and stability, whilst retaining antitumour activity.
We report AFt encapsulation of GW 610, GW 608, and amino acid conjugates of GW 608 to address water solubility and selectivity issues associated with benzothiozoles for anticancer treatment. Amino acid conjugation enhances drug solubility and modifies the charge and polarity, thus allowing optimization of the properties of cargo molecules to achieve increased encapsulation efficiency and controlled sustained release. In this work, we consider nonpolar glycine (Gly), polar serine (Ser), positively charged lysine (Lys), and negatively charged aspartic acid (Asp) conjugated to GW 608. and approximately 110 molecules of GW 608 per AFt cage. We ascribe the observed difference to the increased polarity of GW 608, which hinders encapsulation into AFt with a negatively charged cavity. 24 We note, that encapsulation following one-step addition of the full quantity of test agent reported in the literature 25, 26 resulted in reduced drug loading values, comparable to those published.
For GW 608 derivatives, we also observe some differences in with the negatively charged AFt interface, leading to enhanced encapsulation. Our step-wise encapsulation strategy and modification of charge and polarity of the agent enabled us to achieve approximately two orders of magnitude greater encapsulation efficiency (386 molecules) per AFt cage compared with that reported for gefitinib, 26 doxorubicin, 8, 25 or cisplatin. 27 Improved doxorubicin encapsulation via the reassembly route was recently reported for fusion protein HFt-PAS, achieving 90 molecules per cage 8 ; hence, our encapsulation method offers an advantageous approach for enhanced drug loading.
The poor aqueous solubility of GW 610 was evident from low drug loading of approximately 11%. Improved solubility of the amino acid conjugates increased drug loading more than twofold, with highest value of 25% for the Lys-conjugate. These results confirm that conjugation with amino acids increases encapsulation efficiency due to favourable polarity and enhanced aqueous solubility.
All encapsulated test agents were stable over a period of at least 3 months with respect to drug loading when stored at T = 4°C, as quantified by UV-vis spectroscopy. For samples stored at room temperature, drug release of up to approximately 50% was observed after 7 days storage. At physiologically relevant temperature (T approximately 37°C), all test agents were released from the AFt cage with 100% release observed within 12 hours ( Figure 1C ). Considering the structural sensitivity of AFt to pH, 13 faster release may be anticipated at acidic pH 6.5 associated with tumour micro-environments. However, negligible effect was observed for GW 610 release; indeed, more rapid release of GW 608-Lys at pH 7.4 compared with pH 6.5 was encountered. We postulate that as pH decreases, the proportion of unionized species on Lys reduces, resulting in greater interaction with the negatively charged AFt interior, impeding GW 608-Lys release.
Hence, steady release of benzothiazoles occurs over 12 hours at physiologically relevant pH and is controlled by electrostatic interactions between the agent and the AFt.
| In vitro assessment of therapeutic activity
MTT in vitro growth inhibitory assays were performed to probe the effects of amino acid conjugation and AFt-encapsulation on anticancer Figure 3A and Supporting Information S3).
More polar GW 608 was significantly less potent than GW 610 in all cell lines tested (Table S2 ) and completely inactive in some cell lines.
Reduced lipophilicity of GW 608 is likely to impede diffusion across cell membranes and, combined with potentially lower affinity for AhR, impact negatively on intracellular retention and AhR signal transduction activation.
Conjugation to amino acids increased the potency of GW 608 in all GW 610-sensitive carcinoma cell lines studied (Table 1 and Supporting
Information S3).
Consistent with the selective nature of benzothiazole anticancer activity, negligible activity was observed in insensitive HCT-116 CRC cells and nontransformed MRC-5 fibroblasts (GI 50 > 100μM) ( Table 1 and Supporting Information S3), which express neither inducible nor constitutive CYP 1A1 or CYP 2W1. Following encapsulation, the potency of amino acid conjugates was further enhanced compared with the naked agents; furthermore, the selectivity of GW 610 was retained.
The AFt-GW 608-Gly and AFt-GW 608-Ser are both more active than cence. 29 Cells, seeded at the same density, were treated with benzothiazole test agent at a final concentration of 1μM. Analysis 
| METHODS
All commercially available starting materials were used without further purification. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AV (II) 500 at 500 MHz. High resolution mass spectra (HRMS) were recorded on a Bruker microOTOFII with electrospray ionization (ESI). For cellular uptake studies, cells were seeded at a density of 2.5 × 10 5 cells per well into 12-well plates and allowed 24 hours to adhere. Cells were exposed to test agent (1 μM) for 3, 6 or 9 hours before being washed, harvested and fixed in 3.7% formaldehyde.
| AFt encapsulation and drug release studies
Analyses were performed on a Beckman Coulter MoFlo Astrios EQ, equipped with 355-nm UV laser, 448/59 detection filter, and Summit 5.1 software. For colonogenic assays, 250 cells per well were seeded into six-well plates and allowed 24 hours to attach. Test compounds were added at GI 50 concentrations. After 24-hour exposure, the medium was aspirated and cells washed with PBS (2 × 1 mL) before incubation in medium (2 mL) for 7 to 9 days. Experiments were terminated when colonies more than or equal to 50 cells were observed in control wells. Colonies were washed (PBS, 2 × 1 mL), fixed (methanol, 15 minutes), stained (0.5% methylene blue, 15 minutes), and counted.
| Data analysis

